All In Biotech

NDA 215212 · Hq Spclt Pharma

Meropenem

Meropenem · Intravenous

Last checked: Nov 19, 2026Latest source record: Aug 10, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2023

Jul 26, 2023

Approved uses

1

Original approval plus efficacy supplements

Registered trials

186

58 Phase 3, 27 recruiting

FAERS reports

32,715

31,766 serious, 9,722 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 31, 2026.

Meropenem for Injection is a penem antibacterial indicated for the treatment of bacterial meningitis in pediatric patients 3 months of age and older only. ( 1.1 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Meropenem for Injection and other antibacterial drugs, Meropenem for Injection should only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. ( 1.2 ) 1.1 Bacterial Meningitis (Pediatric Patients 3 Months of Age and Older Only) Meropenem for Injection is indicated for the treatment of bacterial meningitis caused by Haemophilus influenzae , Neisseria meningitidis and penicillin-susceptible isolates of Streptococcus pneumoniae, in pediatric patients 3 months of age and older. Meropenem for injection has been found to be effective in eliminating concurrent bacteremia in association with bacterial meningitis. 1.2 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of Meropenem for Injection and other antibacterial drugs, Meropenem for Injection should only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Mechanism: Meropenem is an antibacterial drug [ see Microbiology ( 12.4 ) ].

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 26, 2023 Original approval · Type 5 - New Formulation or New Manufacturer LetterLabelReview
1 products under this application
  • MEROPENEM · MEROPENEM 2GM/VIAL · POWDER, INTRAVENOUS · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Meropenem" as an intervention, any sponsor and status, largest first.

All 186 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective4,620
  • off label use3,390
  • pyrexia2,230
  • pneumonia1,510
  • septic shock1,472
  • sepsis1,429
  • multiple organ dysfunction syndrome1,356
  • acute kidney injury1,317
  • condition aggravated1,295
  • thrombocytopenia1,153
  • febrile neutropenia1,149
  • respiratory failure1,143

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004101
200599
2006135
2007203
2008228
2009299
2010409
2011737
2012788
2013666
2014658
2015870
20161,203
20171,529
20182,137
20192,342
20202,810
20213,235
20222,870
20232,878
20243,227
20253,082
20262,206

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Meropenem (Meropenem)

2024 spending

$17.5M

Beneficiaries

30,252

94,400 claims

Per beneficiary

$578

$4.31 per unit

View as table
YearSpending
2020$20,597,180
2021$22,377,352
2022$20,251,807
2023$19,803,852
2024$17,498,300

Part B: Meropenem* (Meropenem*) · HCPCS J2185

2024 spending

$108K

Beneficiaries

997

12,122 claims

Per beneficiary

$108

2024 ASP limit $0.38 per unit

View as table
YearSpending
2020$234,839
2021$239,571
2022$222,806
2023$161,358
2024$107,559

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 488 on PubMed

Sponsor: Hq Spclt Pharma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.